• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Optimizing Health Benefit Design and Patient Outcomes In Infertility Management

Opinion
Video

In his final thoughts, Dr. Chervenak provides recommendations for optimal patient outcomes by tailoring design of health benefits.

The following is a perspective from Joseph Chervenak, MD, MBA.

Chervenak believes patient education and awareness of infertility are critical for accessing services. Fertility preservation options like egg freezing are relatively new; it’s been only a decade since they were declared nonexperimental. Patients should understand lifestyle measures to optimize natural conception chances before needing treatment. Recognizing when natural methods fail and turning to medical care is also key.

In addition to knowledge of available services, supporting high-quality, innovative providers helps patients. Avoiding insurance mandates like requiring failed intrauterine insemination cycles before covering in vitro fertilization (IVF) gives qualified physicians autonomy to choose optimal care. More generous coverage for vulnerable groups could also help address disparities. Investing up front in preservation through egg freezing rather than later costly IVF may be cost-effective long-term. Outcome-based plans covering treatment until success versus capping cycles can limit financial uncertainty.

Chervenak argues applying common sense in evaluations for coverage helps too. As an example, patients undergoing preimplantation genetic testing to avoid passing on recessive disorders cannot always afford it, yet the downstream costs of caring for an affected child would be far higher. Removing financial limitations in such clear situations benefits all parties. Overall, multifaceted approaches to education and sensible evaluations of individual circumstances are needed to expand affordable access to quality fertility treatment.

Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.

Related Videos
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
Video 6 - "Failing to Reach Ideal Diabetes Care: Equitable Doesn’t Mean Equal"
Video 5 - "Revising Diabetes Outcome Measures"
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Related Content
© 2024 MJH Life Sciences

All rights reserved.